Percutaneous NG-patch-controlled GLP-1 release by implanted HEKhNORM3 cells reduces insulin levels, attenuates insulin resistance, resets body weight and restores glucose homeostasis of treated mice. This evidence concerns the gene GCG and Insulin resistance.